• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Rectiv (nitroglycerin) ointment 0.4%

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Rectiv (nitroglycerin) ointment 0.4%

  • Profile

Profile

Contact Information

Contact: ProStrakan (Kyowa Kirin)
Website: https://prostrakan.com/

Currently Enrolling Trials

    Show More

    General Information

    Rectiv is a nitroglycerin-based topical ointment. Nitroglycerin is converted by the body into nitric oxide, which can aid in the relaxation of the internal anal sphincter muscle and may have a role in the natural relaxation of muscles in the entire gastrointestinal tract.

    Rectiv is specifically indicated for the treatment of moderate to severe pain associated with chronic anal fissure.

    Mechanism of Action

    Rectiv is a nitroglycerin-based topical ointment. Nitroglycerin forms free radical nitric oxide (NO), which activates guanylate cyclase, resulting in an increase of guanosine 3’, 5’-monophosphate (cyclic GMP) in smooth muscle and other tissues. This leads to dephosphorylation of myosin light chains, which regulates the contractile state in smooth muscle and results in vasodilatation. The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle. Intra-anal application of nitroglycerin reduces sphincter tone and resting intra-anal pressure.

    Side Effects

    Adverse events associated with the use of Rectiv may include, but are not limited to, the following:

    • Headache
    • Dizziness

    Dosing/Administration

    Rectiv is supplied as an ointment for topical administration. The recommended dose of Rectiv is 1 inch of ointment (375 mg of ointment equivalent to 1.5 mg of nitroglycerin) applied intra-anally every 12 hours for up to three weeks.

    Clinical Trial Results


    FDA approval of Rectiv was based on a three-week, double-blind, randomized, multi-center, placebo-controlled study. Subjects with a painful chronic anal fissure for at least six weeks and moderate or severe pain prior to treatment (≥50 mm on the 100mm visual analog scale, VAS) were randomized to receive 0.4% (1.5mg) nitroglycerin or placebo ointment applied to the anal canal every 12 hours. Pain as assessed by the change in VAS from baseline to days 14-18 was lower in subjects receiving 0.4% ointment compared to placebo. The mean change from baseline was 44mm for Rectiv and 37mm for placebo. The difference in the mean change in pain between Rectiv and placebo was -7.0mm.

    Additional Information

    For additional information regarding Rectiv or chronic anal fissures, please visit the Prostrakan web page.

    Approval Date: 2011-06-01
    Company Name: ProStrakan
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing